Business
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
DURHAM, N.C., April 01, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference taking place on April 7, 2025.
About this update from Precision Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/bcff5175e9ed2d276eb231c5520f820f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/72SWd7g0VBZP5NnEL3llXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bcff5175e9ed2d276eb231c5520f820f","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/peWu9SopoB5UxbhJ9L4Vdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/bcff5175e9ed2d276eb231c5520f820f","width":1024,"height":512}},"lazy":false},{"type":"text","content":"DURHAM, N.C., April 01, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference taking place on April 7, 2025.","length":424,"tagName":"p"},{"type":"text","content":"Presentation Details:","length":21,"tagName":"p"},{"type":"text","content":"Date: Monday, April 7, 2025Time: 3:00 PM ET in Track 2Format: PresentationWebcast Registration: Link","length":103,"tagName":"p"},{"type":"text","content":"A live webcast will also be accessible on Precision’s website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcasts will be available for approximately 30 days following the event.","length":257,"tagName":"p"},{"type":"text","content":"About Precision BioSciences, Inc.","length":33,"tagName":"p"},{"type":"text","content":"Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting...